Its isolates have in vitro resistance to most oral antibiotics but generally are susceptible to a limited number of parenteral antibiotics, including tigecycline, imipenem, cefoxitin, and amikacin; treatment with at least 3 active drugs is recommended (see the 2020 practice guideline on the treatment of nontuberculous mycobacterial pulmonary disease).